Alfred Buck University of Zurich Switzerland

Controlled FDG Delivery Study Uses Intego(TM) PET Infusion System to CompareTechniques for Patient ManagementWARRENDALE, Pa., Jan. 6 /PRNewswire/ MEDRAD, Inc., has signed a researchagreement with the University of Zurich to study dynamic PET imaging with theMEDRAD Intego(TM) PET Infusion System.The researchers will utilize MEDRAD'slatest technology to more precisely control the radioactive dose deliveredduring PET imaging procedures.(Logo: http:// )Specifically, the study will examine patients with tumors in the chest orabdomen and compare standard quantitative techniques, such as standard uptakevalue (SUV), with more advanced kinetic and compartmental models.One of theprimary goals of the research is to explore how controlled delivery technologycan enable dynamic imaging by providing additional clinical utility and makingthese advanced techniques more practical.By enabling the benefit ofrepeatable infusion of the prescribed FDG dose to all subjects in the study,the Intego System is a key element in the research."The research will explore the clinical viability of dynamic imaging withPET," said Dr. Alfred Buck, University of Zurich (Switzerland).TheUniversity of Zurich is a leading institution in dynamic PET research, and haslicensed its proprietary FDG delivery technology to MEDRAD for use in theIntego PET Infusion System. The Intego System automatically extracts a patient dose from a multi-dose vialand delivers it directly to the patient, virtually eliminating manual dosepreparation and handling, and the corresponding radiation exposure to thetechnologist inherent in manual preparation.With the Intego System'sdose-on-demand capability, the prescribed dose can be delivered when thepatient and clinician are ready.This enables the clinician to easily andefficiently respond to schedule changes, patient delays, and add-on patients. Innovative features, including real-time dose availability information, anintegrated ionization chamber, and an optional weight-based dose calculation,allow the healthcare provider to more precisely customize each patient's dose. Safety features include a tungsten multi-dose vial shield, a fully lead-linedmobile cart, and an automated saline flush to remove residual FDG from theline after each infusion."Supporting this research with the University of Zurich is an excitingopportunity for us. Today the University enjoys international renown as a place ofeducation and research.

Two thousand lecturers in 140 special institutesprovide the broadest range of subjects and courses available from any Swissseat of higher education. With 24,000 students and 1,900 graduates every year,Zurich is also Switzerland's largest university. The University providesacademic services, works with the private sector and considers itself part ofa national and global network for the acquisition and dissemination ofknowledge. The University of Zurich is member of the League of EuropeanResearch Universities (LERU), an association of the twenty leading Europeanuniversities sharing the values of high-quality teaching within an environmentof internationally competitive research.About MEDRADMEDRAD, Inc., is a worldwide leading provider of medical devices and servicesthat enable and enhance imaging and therapeutic procedures of the human body.For diagnostic imaging, MEDRAD's product offerings include a comprehensiveline of vascular injection systems, magnetic resonance (MR) surface coils andpatient care products, and equipment services. The company also offersproducts used in vascular intervention MEDRAD's total 2007 revenues were $525million. In 2003, MEDRAD received the Malcolm Baldrige National Quality Award,the top honor a U.S.

company can receive for quality and business excellence.The company's world headquarters is near Pittsburgh, Pennsylvania, in theUnited States MEDRAD is an affiliate of Bayer AG. More company information isavailable at Bayer Group is a global enterprise with core competencies in the fields ofhealthcare, nutrition and high-tech materials. Bayer HealthCare, a subsidiaryof Bayer AG, is one of the world's leading, innovative companies in thehealthcare and medical products industry and is based in Leverkusen, Germany.The company combines the global activities of the Animal Health, ConsumerCare, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticalsbusiness operates under the name Bayer Schering Pharma AG.